Die Inhalte stammen aus dem NEJM Journal Watch Oncology & Hematology, der von der NEJM Group, a Division of the Massachusetts Medical Society, hergestellt und veröffentlich wird. Alle Rechte sind vorbehalten und alle Inhalte sind urheberrechtlich geschützt. Universimed und unsere Sponsoren ermöglichen Ihnen den Zugang zu diesen Inhalten als professionelle Unterstützung.
Gynecologic Surgery and Breast Cancer Risk
Risk for breast cancer varied depending on type of surgery and hormone replacement therapy in a large study of women with sisters who had breast cancer.
Hydroxyurea Effective for Stroke Prevention in Children with Sickle Cell Disease in Tanzania
This finding is a call to action for worldwide access to this treatment.
Do Chemoimmunotherapy Clinical Trial Results Apply to Real World Patients with Extensive-Stage Small-Cell Lung Cancer?
They appear to; however, outcomes differ between patients who do and do not meet clinical trial eligibility criteria.
Transplant Outcomes in Acute Myeloid Leukemia
Durable remission and improved survival were demonstrated for patients who achieved very low-level measurable residual disease in peripheral blood prior to allogeneic transplantation.
New Insights into Therapy Selection for Metastatic Castration-Sensitive Prostate Cancer
The benefits of triplet versus doublet regimens varied depending on the combination of agents and on disease burden in this meta-analysis.
TACE Added to Lenvatinib Improves Overall Survival in Hepatocellular Carcinoma
Some adverse events were more frequent with the addition of TACE, but safety was similar with and without TACE overall.
Appendectomy and Hemicolectomy Equivalent in Appendiceal Neuroendocrine Tumors
Resection of lymph node metastases found at hemicolectomy also had no effect on survival.
CAR T-Cell Therapy in Relapsed/Refractory Myeloma
Outcomes were improved with the CAR T-cell agent idecabtagene vicleucel compared with standard treatment regimens.
Gaining MOMENTUM in Myelofibrosis Therapy
Patients receiving the investigational Janus kinase inhibitor momelotinib had improvements in hemoglobin levels, splenomegaly, and disease-related symptoms compared with those receiving danazol.